- Healthy top-line growth of 7.9%
- EBIT up sharply to 22.0 million CHF (+48.4%)
- Margins of 28.2% (EBITDA) and 14.0% (EBIT)
- Disproportionate bottom-line growth to 15.3 million CHF (+62.6%)
- Strong business with NCEs, research chemicals still under pressure, improved results from generic peptides
- Steady growth in sales and profits forecast
